Developing safety criteria for introducing new agents into neoadjuvant trials

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 2817-2823

  DeMichele, Angela ^a   Berry, Donald A ^b   Zujewski, JoAnne ^c   Hunsberger, Sally ^c   Rubinstein, Larry ^c   Tomaszewski, Joseph E ^c   Kelloff, Gary ^c   Perlmutter, Jane ^m   Buxton, Meredith ^d   Lyandres, Julia ^d   Albain, Kathy S ^g   Benz, Chris ^d   Chien, A Jo ^d   Haluska, Paul ⁱ   Leyland Jones, Brian ^k   Liu, Minetta C ⁱ   Munster, Pamela ^d   Olopade, Olufunmilayo ^h   Park, John W ^d   Parker, Barbara A ^e   Pusztai, Lajos ^l   Tripathy, Debu ^f   Rugo, Hope ^d   Yee, Douglas ^j   Esserman, Laura ^d   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g LOYOLA UNIVERSITY CHICAGO   (United States)

^h UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

ⁱ MAYO CLINIC   (United States)

^j UNIVERSITY OF MINNESOTA   (United States)

^k SANFORD RESEARCH   (United States)

^l YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CISPLATIN; ERLOTINIB; GEFITINIB; TAXANE DERIVATIVE;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CLINICAL STUDY; DRUG ANTAGONISM; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; LUNG CANCER; PATIENT SAFETY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK REDUCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; HUMANS; NEOADJUVANT THERAPY; RESEARCH DESIGN;

EID: 84878957922     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2620     Document Type: Review

References (21)

1. DiMasi JA, Grabowski HG. Economics of new oncology drug development. J Clin Oncol 2007;25:209-16. (Pubitemid 350003036)
2. Meropol NJ, Kris MG, Winer EP. The American Ssociety of Clinical Oncology's blueprint for transforming clinical and translational cancer research. J Clin Oncol 2012;30:690-1.
3. Prowell TM, Pazdur R. Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med 2012;366:2438-41.
4. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-27. (Pubitemid 46622110)
5. Esserman LJ, Woodcock J. Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 2011;306:2608-9.
6. Esserman L, Berry D, DeMichele A, Carey L, Davis S, Buxton M, et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL-CALGB 150007/150012, ACRIN 6657. J Clin Oncol 2012;30:3242-9.
7. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012;30:1796-804.
8. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380-8.
9. McQuellon RP, Muss HB, Hoffman SL, Russell G, Craven B, Yellen SB. Patient preferences for treatment ofmetastatic breast cancer: a study of women with early-stage breast cancer. J Clin Oncol 1995;13:858-68.
10. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004;22:777-84. (Pubitemid 41103588)
11. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-94. (Pubitemid 41103589)
12. Tran HT, Zinner RG, Blumenschein GR Jr, Oh YW, Papadimitrakopoulou VA, Kim ES, et al. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced non-small cell lung cancer (NSCLC). Invest New Drugs 2011;29:499-505.
13. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
14. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-52. (Pubitemid 46733081)
15. Tsai TH, Fleming WW. Antagonism of monoamine oxidase inhibitors against norepinephrine acetylcholine and potassium in the isolated nictitating membrane of the cat. J Pharmacol Exp Ther 1965;148:40-7.
16. Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374:2055-63.
17. Osborne CK, Kitten L, Arteaga CL. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 1989;7:710-7. (Pubitemid 19145591)
18. Berry DA. Adaptive clinical trials: the promise and the caution. J Clin Oncol 2011;29:606-9.
19. Rubin EH, Gilliland DG. Drug development and clinical trials[mdash]the path to an approved cancer drug. Nat Rev Clin Oncol 2012;9:215-22.
20. Barker AD, Sigman CC, Kelloff GJ, Hylton NM, Berry DA, Esserman LJ. I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 2009;86:97-100.
21. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol 2011;9:199-207.